|
Immunopathology: evaluation, assessment, and considerations |
|
Enduring |
|
$25.00 |
|
Assessing adversity in immunosafety (preclinical) |
|
Enduring |
|
$25.00 |
|
Assessing adversity in immunosafety (preclinical) |
|
Enduring |
|
$25.00 |
|
Assessing adversity in immunosafety (preclinical) |
|
Enduring |
|
$25.00 |
|
Animal models and species differences (immune system) |
|
Enduring |
|
$25.00 |
|
Animal models and species differences (immune system) |
|
Enduring |
|
$25.00 |
|
Animal models and species differences (immune system) |
|
Enduring |
|
$25.00 |
|
Immunopathology: Evaluation from Discovery to Safety Assessment |
|
Enduring |
|
$25.00 |
|
Definition, history and application of immunosafety in drug development |
|
Enduring |
|
$25.00 |
|
Nonclinical Development of Biologics |
|
Enduring |
|
$25.00 |
|
Natural Killer Cells and their use for Cancer Immunotherapy |
|
Enduring |
|
$25.00 |
|
Immune-related adverse events (clinical) |
|
Enduring |
|
$25.00 |
|
Immune-related adverse events (clinical) |
|
Enduring |
|
$25.00 |
|
Immune-related adverse events (clinical) |
|
Enduring |
|
$25.00 |
|
Diversity of immune responses (impact of age, sex, pregnancy, co-morbidities, etc.) |
|
Enduring |
|
$25.00 |
Facebook
Twitter
LinkedIn
Forward